The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

被引：0

作者：

Al-Sawaf, Othman ^{[1
,2
,3
]}

Fuerstenau, Moritz ^{[1
,2
,3
]}

Giza, Adam ^{[1
,2
,3
]}

Robrecht, Sandra ^{[1
,2
,3
]}

Von Tresckow, Julia ^{[4
]}

Fink, Anna Maria ^{[1
,2
,3
]}

Simon, Florian ^{[1
,2
,3
]}

Tausch, Eugen ^{[5
]}

Schneider, Christof ^{[6
]}

Sivcheva, Liliya ^{[7
]}

Schwarer, Anthony ^{[8
]}

Loscertales, Javier ^{[9
]}

Weinkove, Robert ^{[10
]}

Strumberg, Dirk ^{[11
]}

Kilfoyle, Allanah R. ^{[12
]}

Juliusson, Gunnar ^{[13
]}

Da Cunha-Bang, Caspar ^{[14
]}

Illmer, Thomas

Gregor, Michael ^{[15
]}

Thornton, Patrick ^{[16
]}

Janssens, Ann ^{[17
]}

Tadmor, Tamar ^{[18
]}

Lindstrom, Vesa ^{[19
,20
]}

Staber, Philipp Bernhard ^{[21
]}

Levin, Mark-David ^{[22
]}

Wendtner, Clemens-Martin ^{[23
]}

Kreuzer, Karl-Anton ^{[1
,2
,3
]}

Ritgen, Matthias ^{[24
]}

Stilgenbauer, Stephan ^{[25
]}

Kater, Arnon P. ^{[26
]}

Niemann, Carsten Utoft ^{[27
]}

Fischer, Kirsten ^{[1
,2
,3
]}

Eichhorst, Barbara F. ^{[28
]}

Hallek, Michael ^{[29
]}

机构：

[1] Univ Cologne, Fac Med, Cologne, Germany

[2] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany

[3] Univ Cologne, German CLL Study Grp, Cologne, Germany

[4] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Clin Hematol & Stem Cell Transplantat, Essen, Germany

[5] Ulm Univ, Div CLL, Dept Internal Med 3, Ulm, Germany

[6] Univ Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

[7] Multiprofile Hosp Act Treatment HristoBotev, Dept Internal Med 1, Vratsa, Bulgaria

[8] Box Hill Hosp, Melbourne, Vic, Australia

[9] Hosp Univ La Princesa, Madrid, Spain

[10] Wellington Rerenga Ora Blood & Canc Ctr, Capital & Coast Dist Hlth Board, Wellington, New Zealand

[11] Marien Hosp, Herne, Germany

[12] Palmerston North Hosp, Palmerston North, New Zealand

[13] Lund Univ Canc Ctr, Dept Hematol, Lund, Sweden

[14] Rigshosp, Copenhagen, Denmark

[15] Cantonal Hosp Lucerne, Div Hematol, Luzern, Switzerland

[16] Beaumont Hosp, Canc Trials Ireland, Dept Haematol, RCSI, Dublin, Ireland

[17] Univ Hosp Leuven, Leuven, Belgium

[18] Bnai Zion Med Ctr, Hematol, Haifa, Israel

[19] Helsinki Univ Hosp, Dept Hematol, Ctr Comprehens Canc, Helsinki, Finland

[20] Univ Helsinki, Helsinki, Finland

[21] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Med 1, Vienna, Austria

[22] Albert Schweitzer Hosp, Dept Internal Med, Dordrecht, Netherlands

[23] German CLL Study Grp, Munich Clin Schwabing, Dept Hematol Oncol Immunol Palliat Care Infect Di, Munich, Germany

[24] Univ Schleswig Holstein, Dept Internal Med 2, Kiel, Germany

[25] Univ Hosp Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

[26] Acad Med Ctr, Amsterdam, Netherlands

[27] Copenhagen Univ Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark

[28] Univ Cologne, Cologne, Germany

[29] Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-188827

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：8

共 50 条

[11] Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study
Stilgenbauer, Stephan
Ilhan, Osman
Woszczyk, Darius
Renner, Christoph
Mikuskova, Eva
Boettcher, Sebastian
Tausch, Eugen
Moore, Tom
Tyson, Nicola
Adamis, Helena
Leblonde, Veronique
Bosch, Francesc
Foa, Robin
BLOOD, 2015, 126 (23)
[12] MAJIC: a phase III trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
Ryan, Christine E.
Davids, Matthew S.
Hermann, Richard
Shahkarami, Mina
Biondo, Juliana
Abhyankar, Sarang
Alhasani, Hasan
Sharman, Jeff P.
Mato, Anthony R.
Roeker, Lindsey E.
FUTURE ONCOLOGY, 2022, 18 (33) : 3689 - 3699
[13] Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study
Leblond, Veronique
Cantin, Guy
Cortelezzi, Agostino
Knauf, Wolfgang
Tiab, Mourad
Turgut, Mehmet
Zaritskey, Andrey
Merot, Jean-Louis
Trunzer, Kerstin
Robson, Susan
Gresko, Ekaterina
Stilgenbauer, Stephan
Foa, Robin
Bosch, Francesc
BLOOD, 2017, 130
[14] Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective
Owen, Carolyn J.
Stewart, Douglas A.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (04) : 161 - 170
[15] Fixed-Duration Venetoclax-Obinutuzumab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: Follow-Up of Efficacy and Safety Results From the Multicenter, Open-Label, Randomized, Phase III CLL14 Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 11 - 11
[16] Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Brown, Jennifer R.
Eichhorst, Barbara
Ghia, Paolo
Kater, A. P.
Li, Jianyong
Khurana, Sudha
Elhamy, Mostafa
Wang, Min Hui
Seymour, John F.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S221 - S222
[17] Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
Cho, Sang Kyu
Manzoor, Beenish S.
Sail, Kavita R.
Parise, Helene
Ravelo, Arliene
Shapouri, Sheila
Kapustyan, Tatyana
Sharmokh, Simon
Virabhak, Suchin
Davids, Matthew S.
Johnson, Scott
PHARMACOECONOMICS, 2020, 38 (09) : 941 - 951
[18] Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
Sang Kyu Cho
Beenish S. Manzoor
Kavita R. Sail
Hélène Parisé
Arliene Ravelo
Sheila Shapouri
Tatyana Kapustyan
Simon Sharmokh
Suchin Virabhak
Matthew S. Davids
Scott Johnson
PharmacoEconomics, 2020, 38 : 941 - 951
[19] Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial.
Al-Sawaf, Othman
Zhang, Can
Tandon, Maneesh
Sinha, Arijit
Fink, Anna Maria
Robrecht, Sandra
Tausch, Eugen
Schary, William L.
Ritgen, Matthias
Wendtner, Clemens Martin
Kreuzer, Karl A.
Eichhorst, Barbara
Stilgenbauer, Stephan
Hallek, Michael J.
Fischer, Kirsten
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[20] Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia
Rossi, JF
Van Hoof, A
De Boeck, K
Johnson, SA
Bron, D
Foussard, C
Lister, TA
Berthou, C
Kramer, MHH
Littlewood, TJ
Marcus, RE
Deconinck, E
Montillo, M
Guibon, O
Tollerfield, SM
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) : 1260 - 1267

← 1 2 3 4 5 →